Safety and efficacy of Pure human C1-esterase inhibitor in the treatment of patients with sepsis

Antibiotiki i Khimioterapiya

Volumn 54, Issue 1-2, 2009, Pages 42-46

  Lazareva, N B ^a   Igonin, A A ^a  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Cl esterase inhibitor; Efficacy; Safety; Sepsis

Indexed keywords

ANTIINFECTIVE AGENT; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; HOSPITALIZATION; HUMAN; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; MALE; MICROBIOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; SEPSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT C3; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEPSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67650515003     PISSN: 02352990     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Angus D. C, Linde-Zwirble W. T., Lidicker J. et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Crit Care Med 2001,29:1303-1310.
2. Bone R. C, Balk R. A., Cerra F. B. et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-1655.
3. Zeerleder S., Caliezi C, van Mierlo G. Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. Clin Diagn Lab Immunol 2003; 10:529-535.
4. Liu D., Cat S., Gu J. et al. C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. The Journal of Immunology 2003,171:2594-2601.
5. Davis A.E., Cai S., Liu D. C1 inhibitor: biologic activities that are independent of protease inhibition. Immunobiology 2007; 212:4-5:313-323.
6. Hack C. E., Nuijens R. J., Felt-Bersma F. et al. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med 1989; 86:20
7. Nuijens J., Eerenberg-Belmer A., Huijbregts C. et al. Proteolytic inactivation of plasma CI inhibitor in sepsis. J Clin Invest 1989; 84:443-450.
8. Caliezi C, Zeerleder S., Redondo M. Cl-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med 2002; 30:1722-1728.
9. Hack C. E., Ogilvie A. C, Eisele B. CI inhibitor substitution therapy in septic shock and in vascular leak syndrome induced by high doses of inter-leukin-2. Intensive Care Med 1993; 19:19-28.